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A B S T R A C T   
Discovery of novel cocrystal systems and improvement of their physicochemical properties dominates the current 
literature on cocrystals yet the required end-product formulation is rarely addressed. Drug product 
manufacturing includes complex API solid state processing steps such as milling, granulation, and tableting. 
These all require high mechanical stress which can lead to solid-state phase transformations into polymorphs and 
solvates, or lead to dissociation of cocrystals into their individual components. Here we measured the effect of 
tablet excipients on solid-state processing of a range of pharmaceutical cocrystal formulations. Our findings were 
rationalised using Density Functional Theory (DFT) calculations of intermolecular binding energies of cocrystal 
constituents and co-milling excipients. A 1:1 stoichiometric ratio of API Theophylline (THP) and co-former 4- 
Aminobenzoic acid (4ABA) was co-milled with five different excipients: hydroxypropylmethylcellulose 
(HPMC), polyvinylpyrrolidone (PVP), polyethylene glycol (PEG), lactose, and microcrystalline cellulose (MCC). 
The experiments were carried out in 10 and 25 ml milling jars at 30 Hz for different milling times. Co-milled 
samples were characterised for formation of cocrystals and phase transformation using powder X-ray diffrac-
tion (PXRD) and differential scanning calorimetry (DSC). Our data shows that co-milling in the presence of PEG, 
HMPC or lactose yields purer cocrystals, supported by the calculated stronger excipient interactions for PVP and 
MCC. We identify a suitably-prepared THP–4ABA pharmaceutical cocrystal formulation that is stable under 
extended milling conditions.   
1. Introduction 
Pharmaceutical product manufacturing is complex, requiring chal-
lenging unit operations such as milling, dry mixing, blending, dry 
granulation, and tabletting. In some cases, solid processing may have 
undesired effects on drug substances such as amorphisation of active 
pharmaceutical ingredients (APIs) which makes the drug molecules 
thermodynamically unstable due to high unfavourable free energy 
(Curtin et al., 2013a). Another issue for solid-state processing is change 
in solid form of materials that remain crystalline, i.e., possibility of 
displaying polymorphism via formation of solvates and hydrates (Healy 
et al., 2017; Newman and Zografi, 2014). 
In the pharmaceutical manufacturing chain, milling is primarily used 
for size reduction of APIs (Lyszczarz et al., 2020), as it is challenging to 
obtain API crystals with desired size distribution in the crystallization 
step. However, milling can induce the solid state transformation of API 
molecules which can significantly alter the physicochemical properties 
of drug formulations (Curtin et al., 2013b). Milling can also be used for 
production of drug substances with improved properties such as solu-
bility, compressibility, and tabletability (Szafraniec et al., 2017). Among 
different properties of APIs, solubility is of great importance, as it can 
affect the drug bioavailability. It has been recognized that improving 
bioavailability of the poorly water-soluble APIs is a major challenge for 
the pharmaceutical industry (Abuzar et al., 2018; Loh et al., 2015; Rii-
konen et al., 2018). Different approaches have been developed for 
improving the solubility of APIs, among which solid-state modification 
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has attracted much attention for improving the physicochemical prop-
erties of drugs. Various pathways can be used for solid-state modifica-
tion of drugs including formation of salts, solvates, polymorphic drugs, 
and cocrystals. These methods not only improve the solubility of APIs, 
but can also improve the physicochemical properties of drug formula-
tions, such as compressibility, flowability, and stability. However, a 
thorough understanding of the drug modification process during solid- 
state processing is lacking yet of great importance for drug develop-
ment. For example, it has been reported that the inclusion of low glass 
transition temperature (Tg) polymers as an excipient can lower the 
amorphisation of some APIs during the co-milling process (Curtin et al., 
2013b). 
The cocrystallization method is a promising technique for improving 
the solubility and other properties of oral solid dosage formulations 
(Shaikh et al., 2018b). A pharmaceutical cocrystal is a crystalline single 
phase material composed of a drug (API) with a pharmaceutically 
approved co-former molecule, i.e., two or more different molecular and/ 
or ionic compounds generally in a stoichiometric ratio, which is neither 
a solvate nor a simple salt (Aitipamula et al., 2012). The interaction 
between API and co-former is through hydrogen bonding, in which one 
component is donor and the other one is acceptor. Cocrystals offer 
unique characteristics that can improve drug properties, and have been 
used to overcome the poor solubility of poorly water soluble drugs 
(Shaikh et al., 2018b). 
Different methods have been proposed for the preparation of phar-
maceutical cocrystals, which are divided into two main approaches, i.e., 
solution-based and solvent-less approach. Slow solvent evaporation, 
slow cooling crystallization, and slurry conversion are examples of 
solution-based approaches for pharmaceutical cocrystallization. Neat 
grinding, ball milling, and hot melt extrusion are examples of solvent- 
less approaches. Recently, some hybrid methods have been developed 
for pharmaceutical cocrystallization including sonic-slurry, supercritical 
assisted crystallization, and ultrasound (Berry et al., 2008; Childs et al., 
2008; Padrela et al., 2010). The conventional solution-based approach 
has some drawbacks such as consumption of high amount of solvent, 
contamination of end product by organic solvent residue, and lower 
cocrystal purity. 
Recently, mechanochemical processing has attracted much attention 
and there is a growing demand for this approach in pharmaceutical 
processing, as it is greener and more sustainable. Mechanochemical 
processing via ball milling is a viable process for pharmaceutical coc-
rystallization, as it is a simple process which requires no solvent or 
minimal solvent (Chadwick et al., 2007; Friscic et al., 2006; Hollings-
worth et al., 1994; Trask et al., 2004). The milling process has also been 
used to reduce particle size for lung delivery and other dry powder 
formulations such as hypoglycemic (diabetes) and anti-viral medicines 
(Mitragotri et al., 2014; Santos Cavaiola and Edelman, 2014). Dry 
powder inhaler formulations are made of co-milled API and excipients, 
with the excipients used to improve the drug formulation efficiency, 
dispersibility, and flowability. Mechanochemical preparation of coc-
rystals using ball milling has been investigated in several studies (Ara-
biani et al., 2019; Bysouth et al., 2011). Few studies have characterised 
the thermodynamic stability of the cocrystals during solid-state milling, 
and competitive milling reactions were conducted in the presence of 
functional groups to identify stable cocrystal systems (Fischer et al., 
2015, 2016). Chow et al. demonstrated that jet milling was more 
effective than ball milling in preserving solid state integrity for caffeine- 
glutaric acid (1:1) cocrystals (Chow et al., 2017). In another study by 
Hasa et al., polymer-assisted grinding (POLAG) was used to investigate 
the cocrystal formation and to control polymorphic selection of the 
organic molecules (Hasa et al., 2016, 2015). Furthermore, various 
studies also reported the use of matrix-assisted cocrystallization (MAC) 
with hot melt extrusion (HME) processing, where co-processing of coc-
rystal components with polymer or inert substances was performed to 
produce cocrystals (Boksa et al., 2014; Gajda et al., 2018; Li et al., 2016; 
Shaikh et al., 2018a). Recently Korde et al. investigated a scalable 
continuous solid state shear milling (S3M) for polymer assisted cocrys-
tallization (Korde et al., 2018). 
The current research on pharmaceutical cocrystals has focused on 
the discovery of novel cocrystals with improved properties (Guerain 
et al., 2020; Tomar et al., 2020). However, there is little research on 
understanding the solid processing of cocrystals during various down-
stream processing steps (unit operations) such as milling. API properties 
may be altered due to high mechanical stress in the milling environment 
during solid processing. The mechanical stress may change of API from a 
crystalline to amorphous phase, or trigger polymorphic transformation, 
or dissociation of the cocrystal into its primary components. Moreover, 
the presence of an excipient during co-milling may also have a signifi-
cant effect on the formation of cocrystals again potentially leading to 
amorphization, dissociation or a change in solid form. These phenomena 
can affect the properties of a formulation significantly, which makes 
understanding the formation of cocrystals in the milling process crucial 
for the successful production of pharmaceutical cocrystal products. It 
needs to be controlled, not only to minimise the amorphisation of the 
drug, but also to enhance the purity of the cocrystal. 
Theophylline-4-amino benzoic acid (THP-4ABA) cocrystal has been 
chosen as a model compound for this study. THP is a challenging drug to 
formulate because mechanical processing can affect the polymorphic 
transition, which complicates the design of a robust and reproducible 
manufacturing process. Herein, we study THP solid state processing 
during milling (Fig. 1). The aim of the current study is to provide 
thorough understanding of the co-milling process, using THP and 4ABA 
as the API and co-former, respectively, and five different commonly- 
used excipients: semi-crystalline PEG, MCC and lactose, and amor-
phous excipients PVP and HPMC. Co-milling experiments are conducted 
by milling a 1:1 stoichiometric ratio of THP and 4ABA with various 
ratios of excipients using a ball mill. This allows us to compare the effect 
of the excipients on THP–4ABA cocrystal formation in the co-milled 
mixture. Density functional theory (DFT) binding energy calculations 
supported the experimental observations of purity and stability of the 
cocrystals. 
2. Materials and methods 
2.1. Materials 
Theophylline (anhydrous) was purchased from Alfa Aesar (Lanca-
shire, UK). 4-Aminobenzoic acid (4ABA) was obtained from Acros Or-
ganics, (Geel, Belgium). Polyethylene glycol was obtained from Sigma 
Aldrich (Arklow, Wicklow, Ireland). Metolose 60SH 10,000 (HPMC) was 
kindly provided by Shin-Etsu Chemical Co., Ltd. (Livingstone, UK). 
α-lactose monohydrate was purchased from Sigma-Aldrich (Dorset, UK). 
Microcrystalline cellulose (Avicel PH101) was obtained from Pharma-
trans Sanaq AG (Basel, Switzerland). Polyvinylpyrrolidone (PVP 10) was 
purchased from Sigma-Aldrich (Dorset, UK). 
2.2. Preparation of THP/4ABA cocrystals using solvent evaporation 
In order to prepare the cocrystal sample as a reference for charac-
terizations, a pure cocrystal was prepared by dissolving a 1:1 stoichio-
metric molar ratio of THP and 4ABA in 20 ml of methanol and stirring 
the mixture at a temperature of 64 ◦C until complete dissolution of API 
and coformer in the solvent was achieved. The solvent of the resulting 
clear solution was slowly evaporated under a fume hood for 48 h. The 
obtained solid sample was further dried in an oven at 40 ◦C for 12 h to 
remove any residual solvent. The dried sample was stored in a vacuum 
desiccator prior to characterization. 
2.3. Manufacturing of the cocrystals via ball milling 
Milling of the pharmaceutical cocrystals was carried out using a ball 
milling apparatus (MM 400, Retsch, Germany) equipped with 10 and 25 
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ml milling jars. 1.76 g of equimolar material of THP and 4ABA were 
placed in 10-ml grinding jars (with one grinding ball of diameter 8.74 
mm, 4.06 g) and 25-ml sized grinding jars (containing one grinding ball 
of diameter 13.72 mm, 13.64 g). The mixture was milled at 30 Hz for set 
periods of time (2, 5, 10, 15, 20, and 25 min). The obtained samples 
were then collected and tested for formation of cocrystals using powder 
X-ray diffraction (PXRD) and differential scanning calorimetry (DSC). 
2.4. Co-milling with use of tablet excipients 
In order to understand the influence of excipients on the formation of 
cocrystals, a tablet excipient was included in the formulation. Co-milling 
with various ratios of the tablet excipients HPMC, PVP, PEG, MCC, and 
lactose, with 1.76 g of equimolar material of THP and 4ABA, was carried 
out in a 25 ml grinding jar containing one grinding ball of 13.72 mm 
(13.64 g) for 10 min at 30 Hz. The milled samples were characterised for 
formation of cocrystal using PXRD and DSC. 
2.5. Milling stability 
To examine the effects of over-milling, the formed cocrystals with or 
without excipient were further milled. The milling stability test of coc-
rystals (1.76 g) and cocrystals with excipient (1.84 g) were conducted in 
a 25 ml grinding jar containing one grinding ball of 13.72 mm (13.64 g) 
for 15 min, at 30 Hz. The milled samples were characterised for for-
mation of cocrystal using PXRD and DSC. 
2.6. Differential scanning calorimetry (DSC) 
Thermal analysis of Theophylline and 4-Aminobenzoic acid and the 
ball milled cocrystal was performed using a 214 Polyma DSC (NETZSCH 
Group). Accurately weighed the powder materials loaded into crimped 
DSC aluminum pans. The samples were scanned at a heating rate of 
10 ◦C min− 1 over the temparature of 35–280 ◦C and flow rate of 30 
ml⋅min− 1 of dry nitrogen atmosphere. Analysis was carried out using 
Proteus® software version 7. 
2.7. Powder X-ray diffraction (PXRD) 
Powder XRD patterns of obtained materials was performed using 
PANalytical Empyrean diffractometer with Cu Kα radiation. The tube 
voltage and tube current used were 40 kV and 40 mA, respectively. X-ray 
diffraction patterns were collected over the 2θ range of 5–50◦, with a 
step size of 0.026◦ and a step time of 56 s. In this technique, the powder 
sample was exposed to a beam of monochromatic X-ray radiation, which 
was diffracted and recorded by an X-ray detector. The diffracted data 
was processed and an X-ray powder pattern was plotted. 
2.8. Molecular modelling 
All calculations were carried out using the Vienna Ab initio Simu-
lation Package (VASP) (Hafner, 2007), with plane wave basis sets 
(Kresse and Furthmüller, 1996) and the projector augmented-wave 
(PAW) method (Kresse and Joubert, 1999). Exchange-correlation ef-
fects were treated using density functional theory (DFT) (Argaman and 
Makov, 2000) via the Perdew, Burke, and Ernzerhof (PBE) imple-
mentation of the Generalised Gradient Approximation (GGA) (Perdew 
et al., 1996) with Grimme D3 dispersion corrections (Grimmea et al., 
2010). Single Γ-centred k-point relaxations were carried out using a 
plane wave cut-off of 600 eV and Fermi smearing with smearing width of 
0.1 eV. 
The smallest chemically relevant representation of each excipient 
molecule was used. For PEG, for example, this was a monomer, for MCC 
this was two units. Molecules were placed within 1.6 Å of each other and 
possible binding configurations sampled at rotations of 10◦ (see Fig. 12 
for axes of rotation) to determine the most favourable binding orienta-
tions (based on the lowest ground state energy, similar to previous 
binding energy studies (Song et al., 2018)). Each complex was pre- 
optimised using Avogadro (Hanwell et al., 2012), and then fully opti-
mised in VASP as described above. Once the most favourable molecular 
orientations were determined, binding energies (Eb) were calculated as 
the total ground state energy of the complex minus the ground state 
energies of each isolated component. For example, to calculate the 
binding energy between Lactose and THP, three calculations are 
required: Optimisation of the lactose and THP complex, optimisation of 
lactose alone, and optimisation of THP alone. The binding energy in this 
case is: 
Eb = Elactose:THP − Elactose − ETHP  
Fig. 1. Schematic diagram of solid-state processing of pharmaceutical cocrystals via milling.  
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3. Results 
3.1. Synthesis and characterization of the theophylline cocrystals 
3.1.1. PXRD analysis 
The X-ray diffraction patterns of THP, 4ABA, and the reference 
cocrystal powders are indicated in Fig. 2. The diffraction pattern of THP 
exhibits characteristic peaks at 2θ values of 12.7◦, 14.4◦, 24.2◦, while 
4ABA shows characteristic diffraction peaks at 2θ values of 13.9◦, 15.4◦, 
21.9◦. The THP–4ABA cocrystal displays distinct peaks, not present in 
the patterns of its primary components, at 2θ values of 12.3◦, 14.0◦, 
15.5◦, 26.4◦, 27.5◦, 28.6◦, which shows good agreement with the 
calculated X-ray diffraction pattern. The calculated PXRD pattern of the 
pure THP–4ABA cocrystal and the pattern obtained from the experiment 
are included in the supporting information (Fig. S1). The distinct PXRD 
peaks for THP–4ABA confirm formation of a new solid-state phase, 
formed by interaction between the two primary components. 
3.1.2. DSC analysis 
In order to determine the thermal properties of the primary com-
ponents and the reference cocrystal, DSC analysis was carried out on the 
samples. The DSC patterns of THP, 4ABA and THP–4ABA cocrystals are 
depicted in Fig. 2. THP pattern shows a single endothermic peak at 
temperature of 274 ◦C, whereas 4ABA indicates a single melting point at 
187 ◦C. Also, a single endothermic melting at 170 ◦C with a melting 
enthalpy of 114.7 kJ mol− 1 is observed in the thermogram of the 
THP–4ABA reference cocrystal. 
3.2. Ball milling 
THP–4ABA 1:1 cocrystallization experiments were conducted via 
ball milling using 10 ml and 25 ml steel vessels. The PXRD patterns of 
the milled (10 ml) THP–4ABA crystals are shown in Fig. 3. With 
increased milling duration a decrease was observed in characteristic 
peak intensities of the primary components. The distinct PXRD cocrystal 
peaks become more prominent, and ball milling at 25 min leads to the 
new solid forms of THP–4ABA. Milling carried out in a 25 ml grinding jar 
of a 1:1 physical mixture of THP:4ABA for 5 mins leads to the new solid 
forms of THP–4ABA with unique diffraction pattern distinguishable 
from THP and 4ABA (Fig. 4). To verify the PXRD results, DSC was 
performed for the cocrystals. 
The DSC thermograms for a 1:1 physical mixture of THP:4ABA 
subjected to ball milling in 10 ml grinding jars for 5, 10, 15, 20 and 25 
min are shown in Fig. 3. Examination of the thermal behaviour of the 
material recovered from 5 to 20 min shows two endothermic peaks at 
approximately 168 ◦C and 171 ◦C, demonstrating the possibility of 
eutectic melting and some quantity of pure cocrystals of THP–4ABA. 
Formulations milled at 25 mins showed cocrystal melt and the absence 
of a thermal event attributable to eutectic melting. The melting endo-
therm peak at 171 ◦C corresponds to a highest obtained ΔH of 99.58 J/g. 
Thus, increased milling periods lead to decreasing eutectic melting and 
increasing melting enthalpy, suggesting complete cocrystal formation. 
THP–4ABA 1:1 cocrystallization in a 25 ml grinding jar after 2 min of 
milling showed two melting endotherms at 161.2 ◦C and 168.2 ◦C and 
their respective ΔH were found to be 3.97 J/g and 21.75 J/g (Fig. 4). On 
the other hand, the 1:1 physical mixture of THP: 4ABA milled for 5 mins 
showed a single melting endotherm at 169.7 ◦C with high ΔH of 103.8 J/ 
g, with this single melting endothermal peak corresponding to the 
melting point of THP–4ABA cocrystals. The DSC result supports the 
interpretation of the PXRD results. 
It was found that faster cocrystallization occurred after only 5 mins 
of milling in 25 ml jars in comparison to 25 mins in 10 ml grinding jars. 
This is most likely due to interaction between the larger grinding ball 
with the mill wall generating higher shear forces and friction. Thus, 
increasing mechanical energy leads to increase in reactivity and 
resulting formation of cocrystals, and degradation of cocrystals can be 
avoided by using low residence times (Korde et al., 2018). 
3.3. THP–4ABA cocrystal co-milling and effects of excipients 
The effect on cocrystallization was studied of co-milling physical 
mixtures containing 1:1 THP: 4ABA in the presence of various excipients 
(HPMC, PEG, PVP, MCC, and lactose). The excipient co-milled samples 
were characterised by PXRD and DSC. The PXRD patterns of the co- 
milled and individual cocrystal components using HPMC concentra-
tions ranging from 2 to 50% w/w are shown in Fig. 5. The characteristic 
peaks of the THP–4ABA cocrystal were observed with all the HPMC co- 
milled formulations, indicating that cocrystals can be obtained in the 
presence of varying HPMC content. While we did not perform quanti-
tative analysis, it can be noted that on increasing the HPMC polymer 
Fig. 2. PXRD patterns and DSC thermograms of starting materials and reference cocrystal prepared using solvent evaporation.  
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content, the intensity of the characteristic cocrystal peaks decreased, 
with THP peak counts observed at 2θ = 12.7◦. Hence, the purity of the 
cocrystals decreases with increasing HPMC concentration in the co- 
milled THP–4ABA mixtures. 
Fig. 5 shows the DSC curves of THP–4ABA co-milled with various 
percentages of HPMC. When 2% and 5% HPMC is co-milled with coc-
rystal components, single endothermic peaks at 168.7 ◦C and 167.4 ◦C, 
respectively are observed, which is similar to pure cocrystals. The 
enthalpy of melting for 2% and 5% HPMC are 96.46 J/g and 81.86 J/g, 
which are less than that of the THP–4ABA cocrystal. The DSC thermo-
grams of milled formulation of the THP–4ABA with 10% and 20% HPMC 
showed single melting endotherms at 165.5 ◦C and 165.2 ◦C, with ΔH of 
65.7 J/g and 47.3 J/g, respectively. It is clear that increasing the HPMC 
content from 10 to 20% results in a slight decrease in melting point, with 
high variation in enthalpy. Increasing the HPMC content from 20 to 50% 
significantly decreases the cocrystal melting point to 155.2 ◦C and 
enthalpy of melting to 10.5 J/g (Fig. 5). These observations suggest that 
at higher HPMC percentages, a possible interaction between the HPMC 
and cocrystal components yielding less pure cocrystals (Gajda et al., 
2018). 
Fig. 6 shows the powder XRD patterns of co-milled cocrystal com-
ponents with PVP. The co-milled cocrystal formulation containing 2% 
Fig. 3. PXRD patterns and DSC thermograms of 10 ml ball milled samples at 5–25 min.  
Fig. 4. PXRD patterns and DSC thermograms of 25 ml ball milled samples at 2–5 min.  
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PVP demonstrated a similar intensity of characteristic peaks of the co- 
crystalline phase, which proves it to be complete cocrystallization of 
THP–4ABA. However, PXRD patterns also evidence a very small THP 
peak at 12.7◦. Increasing the PVP content from 2 to 30% with the co- 
milled cocrystal components resulted in a reduced number of cocrystal 
peaks and more peak counts of characteristic THP at 12.7◦. When 30% 
PVP was used, an increased peak intensity of THP was observed 
compared to the cocrystal peaks. These results suggest that co-milling at 
a higher PVP percentage did not lead to complete cocrystallization. It is 
likely that partial amorphisation of cocrystals at higher PVP 
Fig. 5. PXRD patterns and DSC thermograms of HPMC co-milled material samples.  
Fig. 6. PXRD patterns and DSC thermograms of PVP co-milled material samples.  
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concentration hindered complete cocrystal formation upon milling. 
DSC thermograms of the physical mixtures of the THP–4ABA with 
2%, 5%, 10%, 20%, and 30% PVP showed reduction (167.6 ◦C to 
150.6 ◦C) in the cocrystal melting temperature with increasing con-
centration (Fig. 6). Furthermore, the melting enthalpies of PVP co- 
milled cocrystals were significantly reduced (97.7 J/g to 8.8 J/g) as 
polymer concentration increased. Lowest enthalpy values at higher PVP 
concentration suggest partial dissolution of cocrystal components in 
already molten polymer (Coleman and Painter, 1995). 
Results of PXRD for co-milling using PEG are shown in Fig. 7. Co- 
milling 2% to 20% PEG with cocrystal components resulted in diffrac-
tion patterns characteristic of cocrystals. The appearance of cocrystal 
peaks suggests the formation of cocrystals in the presence of PEG. 
Increasing the concentration of PEG in the co-milled mixtures results in a 
slight decrease in characteristic THP–4ABA cocrystal peaks at 14.0◦ and 
27.5◦, with a very low intensity of THP at 12.7◦ detected. This can be 
attributed to unreacted THP. DSC analysis of different amounts of PEG 
co-milled with individual cocrystal components shows two endothermic 
transitions (Fig. 7). The first endothermic peak (melting point of PEG) 
spans from 60.4 ◦C to 58.2 ◦C. The second melting endotherms of the 
THP–4ABA cocrystal decreases with increasing content of the PEG 
(168.9 ◦C to 164.2 ◦C). The decrease in the enthalpy of fusion from 94.86 
to 30.73 J/g with increasing content of the polymer is also observed. 
This is most likely due to the increased miscibility of cocrystal compo-
nents in PEG at higher concentrations. 
For THP–4ABA 1:1 mixtures co-milled using MCC, PXRD showed 
large decrease in the intensity of the characteristic peaks of cocrystals 
with MCC (50 and 67.7%) (Fig. 8). Peak broadening is also observed, 
potentially due to the interaction between MCC and the primary com-
ponents of the cocrystal and may be also associated with high degree of 
amorphisation due to crystal surface defects induced by the milling 
process. The DSC thermogram for THP–4ABA/MCC cocrystals shows 
melting point depression (from 170 ◦C to 162 ◦C) and broader melting 
peaks (Fig. 8), with significant reduction in the melting enthalpies (from 
114.7 kJ to 41.1 J/g). Increase of the MCC content from 50% to 67.7 wt 
% leads to increase in the glass transition temperature (Tg) of MCC from 
119.8 ◦C to 125 ◦C and a decrease of the cocrystal melting peak from 
162 ◦C to 160.8 ◦C. Based on the thermal analyses, the enthalpy of the 
cocrystal peak reduced from 41.10 J/g to 20.88 J/g. This can be 
explained by potential dissolution of cocrystal components in molten 
polymer. 
Fig. 9 shows the PXRD patterns of co-milled cocrystal components 
with lactose. When 50% of lactose is co-milled with cocrystal compo-
nents, PXRD reveals a spectrum characteristic of the pure cocrystal along 
with lactose peaks. On increasing lactose concentration to 67.7% a 
decrease in the peak of cocrystals is observed. The change in the coc-
rystal peak intensity clearly demonstrates a reduction in purity of the 
cocrystallization product. The DSC curve of THP–4ABA/lactose cocrys-
tals (Fig. 9) shows the endothermic peak varied between 152 ◦C and 
137.3 ◦C, with corresponding enthalpy of 95.63 J/g and 95.17 J/g, 
respectively. However, it is not possible to measure the exact melting 
enthalpy for the formed cocrystals, as the dehydration endotherm of 
lactose overlaps with cocrystal melting. 
3.4. The stability of THP–4ABA cocrystals with and without tablet 
excipients 
Milling stability testing was conducted to check the integrity of 
cocrystals formed under mechanochemical conditions. Prepared 
THP–4ABA cocrystals (in the absence of excipients) after a further 15 
mins of milling showed a similar normalised energy of 105.5 J/g, indi-
cating high purity and crystallinity (Fig. 10), i.e., cocrystals that are 
robust and maintain their integrity. Milling stability tests for cocrystals 
co-milled with excipients (15 mins further milling with 5% HPMC, PEG, 
or PVP) showed PXRD intensity peaks that still resemble the original 
cocrystal and the thermograms showed melting peaks and enthalpies 
that were similar to cocrystals (Fig. 11). Therefore, no phase separation 
or dissociation of cocrystals occurred, suggesting optimal co-milling 
conditions. 
3.5. Density functional theory (DFT) modelling 
In order to rationalise the experimental results at the nanoscale, 
intermolecular binding energies were calculated using dispersion- 
Fig. 7. PXRD patterns and DSC thermograms of PEG co-milled material samples.  
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corrected DFT. Binding energies between pairs of excipient molecules 
were first calculated, as well as binding energies between the excipient 
molecules and the API, the co-former, and the cocrystal molecular 
complex (Fig. 12), respectively (Table 1). 
Generally speaking, smaller-magnitude binding energies with the 
excipient result in more stable cocrystal formation. If either the co- 
former, the API, or the hydrogen-bonded complex bind too strongly to 
the excipient molecules, crystallisation will be inhibited via dissociation 
or amorphization (Fig. 13a and b) (Alhalaweh et al., 2012; Seaton and 
Parkin, 2011). 
Fig. 8. PXRD patterns and DSC thermograms of MCC co-milled material samples.  
Fig. 9. PXRD patterns and DSC thermograms of lactose co-milled material samples.  
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The binding energies calculated by DFT show a clear trend in the 
affinities of the excipient molecules for the THP–4ABA complex, in the 
order PEG < HPMC < lactose < MCC < PVP. Fig. 13 shows the most 
favourable molecular orientations that were used to calculate the 
intermolecular interactions. As the binding energies shown in Table 1 
are for the strongest possible interactions in each case, it is important to 
note that in a standard ball-milling process multiple molecular geome-
tries will interact. Here we discuss the strongest molecular interactions 
for both the API and co-former with each excipient, representing their 
interactions prior to forming the molecular complex. For studying the 
interactions between excipients and the THP–4ABA complex the known 
optimised configuration is used, where two hydrogen bonds are formed 
between the API and co-former i.e. (O-H—O and N-O—H, shown as 
dashed yellow lines in Fig. 12). It is possible that less probable geome-
tries will interact in a large scale process, but the results demonstrate 
that the strongest/most probable interactions successfully predict co- 
crystal stability. 
PEG consistently has the lowest binding energy with all molecules, 
due to the low number of interaction sites available for this small 
molecule. The intermolecular PEG-PEG binding energy is − 28.4 kJ/mol, 
which is half the strength of the HPMC intermolecular binding energy 
(− 60.9 kJ/mol), and one third of that of PVP (− 91.1 kJ/mol). We see an 
almost identical trend in binding energy between the excipients and the 
THP–4ABA complex, with binding energies of − 17.0 kJ/mol, − 32.9 kJ/ 
mol, and − 54.6 kJ/mol for PEG, HPMC, and PVP, respectively. 
Lactose has weaker binding energies than MCC for both the inter-
molecular and THP–4ABA interactions, correlating with more stable 
cocrystal formation when using lactose as an excipient (measured en-
thalpies from above). The difference in binding energies between these 
molecules for each instance is relatively small. The intermolecular 
Fig. 10. PXRD patterns and DSC thermograms of further milled 25 ml samples.  
Fig. 11. PXRD patterns and DSC thermograms of further milled 25 ml co-milled samples.  
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binding energies differ by only 6.4 kJ/mol, and with THP–4ABA is only 
3.8 kJ/mol. However, the binding energies of lactose are consistently 
lower in all cases, except for with 4ABA. Contrastingly, when we look at 
the binding energies between these molecules and 4ABA alone, we see a 
50% increase in binding strength for lactose vs. MCC, but the complex 
geometry formed is not feasible in the cocrystal as the THP terminus 
binds with the excipient, blocking the excipient/co-former interaction. 
The computed structures show that only HPMC and lactose form 
hydrogen bonds with the API/co-former complex. PEG has the weakest 
binding with THP–4ABA, with just van der Waals contacts, (Fig. 13 c and 
d) which is also the case for MCC and PVP. Given the experimentally 
measured superior performance of lactose relative to MCC, our data 
emphasises that some low level of hydrogen bonding between the 
excipient and component molecules is necessary for stable cocrystal 
formation, coupled with overall mild excipient–API/co-former interac-
tion strengths. Recommended future work includes classical molecular 
dynamics simulations of hundreds of API/co-former molecules and large 
excipient surfaces, similar to Verma et al. (2018), to investigate the ki-
netics of these binding interactions. Based on this study we identify some 
key design rules for effective cocrystal-excipient interactions in large- 
scale processing (Fig. 13e). To reduce the probability of amorphisation 
a weak binding energy between the cocrystal complex and the excipient 
molecule is recommended. This can be due to exclusively vdW contacts 
or minimal hydrogen bonding. The easiest way to achieve this is to use 
an excipient with a lower molecular weight than the cocrystal complex, 
but this is not a requirement for stable cocrystal formation. 
4. Discussion 
Successful development of pharmaceutical cocrystal drug products 
remains something of a “black art” (Shaikh et al., 2018b) despite de-
cades of intense research on pharmaceutical cocrystals. In the pharma-
ceutical manufacturing process, active pharmaceutical ingredients 
(APIs) and excipients undergo various mechanical operations such as 
milling, mixing, granulation and compression which are responsible for 
causing potential interactions of the drug with the excipients. On the 
other hand, solid-state phase transformations can affect the quality and 
performance of the final product. The pharmaceutical milling process is 
the most common unit operation to achieve uniform size reduction for 
better solid oral products (Shaikh et al., 2018a). Milling and co-milling 
of pharmaceutical cocrystals can often result in solid-state phase trans-
formations and dissociation into its individual components. Therefore, 
this study attempts to create an understanding of cocrystal API solid 
state processing with a variety of excipients in milling environment. 
Cocrystal formation occurred in the presence of all five commonly 
used excipients. However, the purity of the cocrystals varied according 
to the type of excipient and the concentration used in the formulation. 
2% of polymer excipients PVP, HPMC, PEG all showed increased coc-
rystal peak intensities and higher melting enthalpies. Increasing the 
polymer excipient concentration in the cocrystal formulation from 20 to 
50% wt. leads to significant broadening in cocrystal peaks that lower the 
observed melting temperature, and greatly reduced intensities of coc-
rystal peaks that lower the enthalpy. This suggests that when less 
polymer excipient is co-milled with the cocrystal components, the 
intermolecular interaction between API and co-former is stronger than 
the interaction with the excipients, thus producing purer cocrystals. 
Increasing the co-milled polymer concentration (20 to 50% wt.) allowed 
for a higher probability of interaction between the excipient and the 
cocrystal components which leads to partial amorphisation of cocrystals 
and may further inhibit the molecular interaction between the API and 
co-former (Shaikh et al., 2019). PXRD and DSC results revealed that 
cocrystal formulations co-milled with HPMC or PEG produced higher- 
purity cocrystals compared to PVP. This may be because the cocrystal 
components are less miscible in HPMC and PEG in comparison with PVP 
during the co-milling process. Diluents (lactose and MCC) were co- 
milled at increased ratios to evaluate the maximum concentration at 
which cocrystals would form. API and co-former co-milled with lactose 
diluent retained cocrystal characteristics with increased intensity sug-
gesting highest purity cocrystals. This is further supported by the higher 
enthalpy values of the samples co-milled with lactose in comparison 
with MCC. Therefore, co-milling with crystalline lactose has the poten-
tial to control the crystalline form of the cocrystal. Although co-milling 
of cocrystals in the presence of excipients can cause amorphization and 
polymorphism, co-milling with HPMC, PEG and lactose has the potential 
to significantly inhibit these changes. 
DFT calculations confirm that PEG, HPMC, and lactose are the most 
suitable excipients based on their weaker binding to the cocrystal 
complex. The generally low-magnitude binding energies of all excipients 
(both amorphous and semi-crystalline) with the cocrystal complex and 
subcomponents reduces the probability of dissociation and amorphisa-
tion during processing and increases the probability of stable cocrystal 
formation. 
A thorough characterisation of cocrystal physicochemical properties 
was achieved, substantiated by computational modelling of potential 
interactions between the excipient and cocrystal components that can 
affect the cocrystal product performance. Our studies in model cocrystal 
Fig. 12. Example unit cell showing a starting geometry between THP-4ABA 
and MCC. The excipient molecule is orientated so that the molecular back-
bone is parallel to the arbitrary a axis (shown by the black line). The edge of the 
complex is brought within less than 2 Å of the excipient backbone. The central 
axis of the molecular complex, shown as a purple line, is rotated about each 
excipient interface to determine the strongest molecular interactions. (For 
interpretation of the references to colour in this figure legend, the reader is 
referred to the web version of this article.) 
Table 1 
Intermolecular binding energies (kJ/mol) calculated by DFT.  
Molecule HPMC Lactose PEG PVP MCC 
HPMC − 60.9     
Lactose  − 74.5    
PEG   − 28.4   
PVP    − 91.1  
MCC     − 80.9 
THP − 47.6 − 33.9 − 20.4 − 39.2 − 43.9 
4ABA − 86.9 − 66.9 − 30.9 − 38.3 − 44.6 
Cocrystal − 32.9 − 35.8 − 17.0 − 54.6 − 39.6  
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formulation co-milling (THP–4ABA) have demonstrated that the type of 
excipient, excipient crystallinity, molecular weight, and concentration 
greatly influence cocrystal purity. The results showed that amorphiza-
tion is reduced and purity of cocrystals is enhanced by co-milling with 
PEG HPMC, or lactose. Future work could further consider the possible 
role of adsorbed water on the structures, using for example, more 
detailed DFT models, X-ray diffraction studies, and thermogravimetric 
analysis (TGA) of both the pure excipients and the milled reaction 
mixture. 
5. Conclusions 
In the present study we investigated the robustness of a theophylline 
pharmaceutical cocrystal (with 4-aminobenzoic acid co-former) during 
Fig. 13. Molecular mechanism of pure cocrystal formation during milling, based on optimised complex-excipient interactions calculated using DFT. (a) Example 
starting structure showing the THP-4ABA complex placed within 1.6 Å of a Lactose excipient molecule in ball-and-stick representation. Carbon atoms are colored 
grey, nitrogen are blue, hydrogen are white, and oxygen are red. (b) Optimised THP–4ABA/Lactose binding. Hydrogen bonds are shown as yellow lines. (c) 
Optimised THP–4ABA interaction with PEG. (d) Optimised THP–4ABA interaction with PEG with atoms shown as van der Waals space-filling spheres. (e) The balance 
of molecular properties that make an ideal excipient for large scale manufacturing processes such as milling. (For interpretation of the references to colour in this 
figure legend, the reader is referred to the web version of this article.) 
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a milling process with a variety of excipients. Using DSC and PXRD, the 
formation of cocrystals during co-milling has been investigated. Our 
results indicate that co-milling with excipients generally leads to coc-
rystallization, with amorphization more likely in the presence of PVP 
and MCC. Cocrystal co-milling with an excipient showed the limiting 
excipient concentration required to get the highest purity of cocrystals, 
producing co-milled cocrystals that are robust and withstand the milling 
process. Molecular-level analysis of the corresponding cocrystal struc-
tures revealed that well-performing PEG has the weakest intermolecular 
binding energy with all molecules, whereas the destructive PVP excip-
ient showed the strongest interaction. Finally, this study will contribute 
to overall understanding of cocrystal co-milling and will also boost 
future cocrystal drug product development. 
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